Operating
Payments for Employee Equity Performance Awards
Royalty Pharma Payments for Employee Equity Performance Awards increased by 6.8% to $9.70M in Q1 2026 compared to the prior quarter.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ1 2023
Last reportedQ1 2026May 6, 2026
How to read this metric
Fluctuations reflect changes in compensation structure and the achievement of performance targets.
Detailed definition
Represents cash payments made to employees related to equity-based performance awards. This reflects the cost of incenti...
Peer comparison
Comparable to cash-settled share-based compensation expenses at other public companies.
Metric ID:
operating_payments_for_employee_equity_performance_awardsHistorical Data
11 periods
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $173.00K | $1.70M | $9.08M | $9.70M |
| QoQ Change | — | — | — | — | — | — | — | — | +879.8% | +435.4% | +6.8% |
Range$0.00 – $9.70M
Current Streak3+ quarters growth
Payments for Employee Equity Performance Awards at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's payments for employee equity performance awards?
- Royalty Pharma (RPRX) reported payments for employee equity performance awards of $9.70M in Q1 2026.
- What does payments for employee equity performance awards mean?
- Cash paid to employees for performance-based equity awards.